The 17-year-old has grown up in the spotlight thanks to her famous parents' many TV projects over the years, with her birth ...
The Food and Drug Administration approved a medication this week known as VYKAT XR to treat hyperphagia — or an incessant feeling of hunger — in kids and adults with Prader-Willi syndrome. The ...
Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as Vykat XR – to treat extreme hunger in patients with Prader-Willi ...
Diazoxide choline extended-release is the first FDA-approved therapy to address hyperphagia in Prader-Willi syndrome. Soleno Therapeutics announced the medication will be available beginning in April.
Though the exact mechanism of action is unclear, it is believed that in patients with Prader-Willi syndrome, diazoxide choline reduces hyperphagia through activation of the adenosine triphosphate ...
Stacy Ward, CEO of the Prader-Willi Syndrome Association | USA, and Susan Hedstrom, Executive Director of the Foundation for Prader-Willi Research, also acknowledged the approval as a pivotal ...
Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for Prader-Willi syndrome (PWS), a rare genetic disorder that causes excessive appetite and obesity. Vykat XR (diazoxide ...
"The FDA approval of Vykat XR is an incredible achievement for the entire PWS [Prader-Willi syndrome] community. I am excited to have Vykat XR available to help treat hyperphagia, which is the ...
The drug, to be called Vykat XR, treats hyperphagia, the hallmark symptom of the Prader-Willi syndrome, a genetic disorder caused by full or partial deletions on chromosome 15 that affect the ...